Breaking the fibrotic code: Nanotechnology-driven advances in renal fibrosis therapy
Biomaterials · 2026-04 · 327 · 123738
DOI: 10.1016/j.biomaterials.2025.123738 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomaterials, 2026-04. Verfasst von Minna Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Fundamental Medical Science Research Laboratories, The 940th Hospital Joint Logistics Support Forces of PLA & Key Laboratory of Stem Cells and Gene D…. Hauptthemen laut MEDLINE: Nanotechnology. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 313 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Gansu Province.
Abstract (Originalsprache)
Renal fibrosis, a hallmark of chronic kidney disease progression, arises from complex pathogenic mechanisms involving inflammatory activation, myofibroblast proliferation, and excessive extracellular matrix deposition. Current treatment is limited by poor bioavailability and off-target effects. This review elaborates on how nanotechnology can overcome these obstacles by delivering targeted drugs to fibrotic kidneys. The pathogenesis of renal fibrosis was systematically analyzed, emphasizing the heterogeneity and plasticity of myofibroblast origin and activation. Then the mechanisms of nanoparticle transport in the kidneys, particularly the impact of the fibrotic environment on nanoparticle transport were focused on. The design principles of active and passive targeting of the kidneys by nano-delivery systems in the context of fibrosis are also discussed. Additionally, emerging renal-targeted nanocarriers are summarized, and therapeutic nanomedicines for fibrosis relief are rigorously evaluated. Despite the progress made, challenges remain in the design optimization of nanocarriers, the intelligence of nanomaterials, and the clinical translation of nanomedicines. Future research directions should focus on AI-assisted nanocarrier design, innovation in intelligent nanomaterials, and the application of humanized models. In conclusion, this review highlights the potential of nanomedicine in reshaping the treatment of renal fibrosis and provides practical innovative insights for promoting in-depth and translational research in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fundamental Medical Science Research Laboratories, The 940th Hospital Joint Logistics Support Forces of PLA & Key Laboratory of Stem Cells and Gene Drugs of Gansu Province, Lanzhou, Gansu Province, China. Electronic add…
- Department of Pharmacy, The 940th Hospital Joint Logistics Support Forces of PLA, Lanzhou, Gansu Province, China. Electronic address: lxltdcqgbtj2019@163.com.
- Department of Pharmacy, The 940th Hospital Joint Logistics Support Forces of PLA, Lanzhou, Gansu Province, China; Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, Chi…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Gansu Province
Zitieren
APA
Liu, M., Li, X., Gao, Y., Wei, Z., Ma, J., Zhang, L., Zhang, X., Chen, K., & Liu, T. (2026). Breaking the fibrotic code: Nanotechnology-driven advances in renal fibrosis therapy. Biomaterials, 327, 123738. https://doi.org/10.1016/j.biomaterials.2025.123738
Vancouver
Liu M, Li X, Gao Y, Wei Z, Ma J, Zhang L, et al. Breaking the fibrotic code: Nanotechnology-driven advances in renal fibrosis therapy. Biomaterials. 2026;327:123738. doi:10.1016/j.biomaterials.2025.123738
BibTeX
@article{Liu2026,
author = {Liu, Minna and Li, Xiaolin and Gao, Yuhai and Wei, Zhenlong and Ma, Jun and Zhang, Lu and Zhang, Xu and Chen, Keming and Liu, Tianlong},
title = {Breaking the fibrotic code: Nanotechnology-driven advances in renal fibrosis therapy},
journal = {Biomaterials},
year = {2026},
volume = {327},
pages = {123738},
doi = {10.1016/j.biomaterials.2025.123738}
}
EUVIMED